AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 3 analysts
Fundamentals
Fundamentals institutional score is 91 using growth durability 90.7.
Valuation
Valuation institutional score is 54 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 76 using mean target upside 10.0%; dispersion penalty 5.3; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 48 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 6 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and analyst consensus provide support, while valuation and technical structure remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 27.3% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.74). Confidence: 87%.
Live forward EPS implies next-12-month EPS of ₹52.44. Applying the stock's normalized valuation corridor produces a fair range of ₹2,448.95 to ₹2,830.19, with base value near ₹2,607.32 (+25.3% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹52.44
Forward P/E
39.7x
Base Fair Value
₹2,607.32
Fair Range
₹2,448.95 - ₹2,830.19
Upside To Base
+25.3%
Estimate Source
Live forward EPS
Growth Estimate
+30.2%
5Y Average
54.29
Current
63.29
Overvalued
53.97
Undervalued
46.70
5Y Average
35.23
Current
41.52
Overvalued
39.81
Undervalued
31.34
5Y Average
—
Current
17.04
Overvalued
19.60
Undervalued
14.49
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
TORRENT PHARMACEUTICALS L TORNTPHARMPharmaceuticals | +54.8% | 13.9% | 78.7x Premium | +104% vs avg | +36.2% |
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.2x Fair | -9% vs avg | -2.7% |
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.7x Fair | -12% vs avg | +10.6% |
LUPIN LIMITED LUPINPharmaceuticals | +32.0% | 18.5% | 19.0x Undervalued | -51% vs avg | +21.5% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.4x Fair | -8% vs avg | +11.2% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Fair | -2% vs avg | -15.6% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Fair | 0% vs avg | +31.7% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 29.2x Undervalued | -24% vs avg | -3.9% |
CORONA REMEDIES LIMITED trades at a premium (64.0x vs peer avg 38.5x), implying higher growth or quality expectations from the Pharmaceuticals cohort. Peers include TORRENT PHARMACEUTICALS L, CIPLA LTD, LARSEN & TOUBRO LTD. — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹422 CrJun 2026Latest net profit
₹60 CrJun 2026Latest EPS
₹9.83Jun 2026Net margin
22.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales + | 314 | 298 | 294 | 347 | 361 | 342 | 353 | 422 |
| Expenses + | 247 | 228 | 239 | 277 | 283 | 259 | 291 | 329 |
| Operating Profit | 67 | 69 | 54 | 70 | 78 | 83 | 62 | 93 |
| OPM % | 21% | 23% | 18% | 20% | 22% | 24% | 18% | 22% |
| Other Income + | 2 | 1 | 1 | 2 | 2 | -17 | 4 | 3 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 | 13 |
| Profit before tax | 57 | 58 | 43 | 61 | 70 | 55 | 54 | 80 |
| Tax % | 25% | 23% | 28% | 24% | 25% | 25% | 17% | 25% |
| Net Profit + | 43 | 45 | 31 | 46 | 52 | 41 | 45 | 60 |
| EPS in Rs | 7.03 | 7.32 | 5.12 | 7.59 | 8.53 | 6.74 | 7.37 | 9.83 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome